(MNKD) MannKind - Ratings and Ratios
Inhaled,Insulin,Diabetes,Respiratory
MNKD EPS (Earnings per Share)
MNKD Revenue
Description: MNKD MannKind
MannKind Corp (NASDAQ:MNKD) is a biotechnology company listed on the NASDAQ exchange, operating in the United States. The companys stock performance is characterized by a relatively high beta of 1.017, indicating a moderate level of volatility in relation to the overall market.
From a fundamental analysis perspective, MannKind Corp has a market capitalization of approximately $1.049 billion USD, with a price-to-earnings (P/E) ratio of 31.09 and a forward P/E ratio of 23.47. These metrics suggest that the companys stock is trading at a premium relative to its current earnings, but the forward P/E ratio indicates potential for earnings growth. The absence of Return on Equity (RoE) data may indicate that the company is not yet profitable or has negative equity.
Key economic drivers for MannKind Corp include the demand for its pharmaceutical products, particularly Afrezza, an inhaled insulin product used for the treatment of diabetes. The companys revenue growth and profitability are closely tied to the market adoption and sales performance of Afrezza. Key Performance Indicators (KPIs) to watch include revenue growth rate, gross margin, and operating expenses as a percentage of revenue.
To evaluate the investment potential of MannKind Corp, it is essential to analyze the companys financial statements, management team, and industry trends. A thorough analysis of the companys income statement, balance sheet, and cash flow statement can provide insights into its financial health, profitability, and cash generation capabilities. Additionally, assessing the competitive landscape, regulatory environment, and market trends in the biotechnology industry can help investors make informed decisions.
MNKD Stock Overview
| Market Cap in USD | 1,761m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2004-07-28 |
MNKD Stock Ratings
| Growth Rating | 3.87% |
| Fundamental | 76.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -30.7% |
| Analyst Rating | 4.86 of 5 |
MNKD Dividends
Currently no dividends paidMNKD Growth Ratios
| Growth Correlation 3m | 62.2% |
| Growth Correlation 12m | -85.7% |
| Growth Correlation 5y | 43% |
| CAGR 5y | 19.05% |
| CAGR/Max DD 3y | 0.35 |
| CAGR/Mean DD 3y | 0.87 |
| Sharpe Ratio 12m | -1.06 |
| Alpha | 0.07 |
| Beta | 0.876 |
| Volatility | 68.29% |
| Current Volume | 2579.4k |
| Average Volume 20d | 4173.7k |
| Stop Loss | 5 (-7.2%) |
| Signal | -0.69 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (32.8m TTM) > 0 and > 6% of Revenue (6% = 18.1m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 2.94pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 55.41% (prev 99.02%; Δ -43.60pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 34.5m > Net Income 32.8m (YES >=105%, WARN >=100%) |
| Net Debt (-10.2m) to EBITDA (79.1m) ratio: -0.13 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (311.5m) change vs 12m ago 14.07% (target <= -2.0% for YES) |
| Gross Margin 74.91% (prev 71.29%; Δ 3.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 70.54% (prev 55.96%; Δ 14.58pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.10 (EBITDA TTM 79.1m / Interest Expense TTM 32.7m) >= 6 (WARN >= 3) |
Altman Z'' -28.67
| (A) 0.41 = (Total Current Assets 279.0m - Total Current Liabilities 111.8m) / Total Assets 411.7m |
| (B) -7.74 = Retained Earnings (Balance) -3.19b / Total Assets 411.7m |
| warn (B) unusual magnitude: -7.74 — check mapping/units |
| (C) 0.16 = EBIT TTM 68.5m / Avg Total Assets 427.8m |
| (D) -6.82 = Book Value of Equity -3.18b / Total Liabilities 466.7m |
| Total Rating: -28.67 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.79
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 1.46% = 0.73 |
| 3. FCF Margin 9.54% = 2.39 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda 4.94 = -2.50 |
| 6. ROIC - WACC (= 43.83)% = 12.50 |
| 7. RoE data missing |
| 8. Rev. Trend 96.20% = 7.21 |
| 9. EPS Trend 89.27% = 4.46 |
What is the price of MNKD shares?
Over the past week, the price has changed by -3.23%, over one month by +41.47%, over three months by +43.73% and over the past year by -17.84%.
Is MannKind a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MNKD is around 5.03 USD . This means that MNKD is currently overvalued and has a potential downside of -6.68%.
Is MNKD a buy, sell or hold?
- Strong Buy: 6
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MNKD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.7 | 79.4% |
| Analysts Target Price | 9.7 | 79.4% |
| ValueRay Target Price | 5.6 | 3.5% |
Last update: 2025-09-04 04:43
MNKD Fundamental Data Overview
CCE Cash And Equivalents = 179.0m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 52.1818
P/E Forward = 44.2478
P/S = 5.8369
P/EG = -0.23
Beta = 1.017
Revenue TTM = 301.7m USD
EBIT TTM = 68.5m USD
EBITDA TTM = 79.1m USD
Long Term Debt = 354.9m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 36.2m USD (from shortTermDebt, last quarter)
Debt = 391.1m USD (Calculated: Short Term 36.2m + Long Term 354.9m)
Net Debt = -10.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.97b USD (1.76b + Debt 391.1m - CCE 179.0m)
Interest Coverage Ratio = 2.10 (Ebit TTM 68.5m / Interest Expense TTM 32.7m)
FCF Yield = 1.46% (FCF TTM 28.8m / Enterprise Value 1.97b)
FCF Margin = 9.54% (FCF TTM 28.8m / Revenue TTM 301.7m)
Net Margin = 10.87% (Net Income TTM 32.8m / Revenue TTM 301.7m)
Gross Margin = 74.91% ((Revenue TTM 301.7m - Cost of Revenue TTM 75.7m) / Revenue TTM)
Tobins Q-Ratio = -0.62 (set to none) (Enterprise Value 1.97b / Book Value Of Equity -3.18b)
Interest Expense / Debt = 1.58% (Interest Expense 6.19m / Debt 391.1m)
Taxrate = 9.60% (2.93m / 30.5m)
NOPAT = 61.9m (EBIT 68.5m * (1 - 9.60%))
Current Ratio = 2.50 (Total Current Assets 279.0m / Total Current Liabilities 111.8m)
Debt / EBITDA = 4.94 (Net Debt -10.2m / EBITDA 79.1m)
Debt / FCF = 13.58 (Debt 391.1m / FCF TTM 28.8m)
Total Stockholder Equity = -100.6m (last 4 quarters mean)
RoA = 7.97% (Net Income 32.8m, Total Assets 411.7m )
RoE = unknown (Net Income TTM 32.8m / Total Stockholder Equity -100.6m)
RoCE = 26.95% (Ebit 68.5m / (Equity -100.6m + L.T.Debt 354.9m))
RoIC = 51.65% (Ebit 68.5m / (Assets 411.7m - Current Assets 279.0m))
WACC = 7.82% (E(1.76b)/V(2.15b) * Re(9.24%)) + (D(391.1m)/V(2.15b) * Rd(1.58%) * (1-Tc(0.10)))
Shares Correlation 3-Years: 66.67 | Cagr: 1.68%
Discount Rate = 9.24% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 65.24% ; FCFE base≈24.5m ; Y1≈16.1m ; Y5≈7.35m
Fair Price DCF = 0.39 (DCF Value 119.5m / Shares Outstanding 306.8m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 89.27 | EPS CAGR: 121.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 96.20 | Revenue CAGR: 36.04% | SUE: N/A | # QB: None
Additional Sources for MNKD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle